You just read:

Novartis announces that Xolair® is approved in Canada as a licensed therapy for chronic idiopathic urticaria (CIU) patients unresponsive to antihistamines

News provided by

Novartis Pharmaceuticals Canada Inc.

Aug 28, 2014, 09:00 ET